High-performance liquid chromatographic separation of cadralazine from its potential metabolites and degradation products. Quantitation of the drug in human plasma and urine.
The chromatographic behaviour of cadralazine and its potential metabolites and degradation products with respect to pH, buffer molarity and composition of eluent is described. A selective method with an adequate sensitivity for the determination of the drug in human plasma and urine is also reported. The method includes extraction of biological fluids with chloroform and the analysis of extracts on a reversed-phase column with isocratic elution and detection at 254 nm. The method has been applied to the analysis of plasma and urine of a patient administered a single oral dose of 30 mg of cadralazine.
D000959:Antihypertensive Agents / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine; D002021:Buffers; D055598:Chemical Phenomena; D002621:Chemistry; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D011724:Pyridazines / Q000032:analysis* / Q000097:blood / Q000378:metabolism / Q000652:urine
D000959:Antihypertensive Agents; D002021:Buffers; D011724:Pyridazines; C031877:cadralazine